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Antibodies to antigens in the Kell blood group system are usually 
immunoglobulin G, and, notoriously, anti-K, anti-k, and anti-Kpa 
can cause severe hemolytic transfusion reactions, as well as severe 
hemolytic disease of the fetus and newborn (HDFN). It has been 
shown that the titer of anti-K does not correlate with the severity 
of HDFN because, in addition to immune destruction of red 
blood cells (RBCs), anti-K causes suppression of erythropoiesis 
in the fetus, which can result in severe anemia. We report a case 
involving anti-Kpa in which one twin was anemic and the other 
was not. Standard hemagglutination and polymerase chain 
reaction (PCR)-based tests were used. At delivery, anti-Kpa was 
identified in serum from the mother and twin A, and in the eluate 
prepared from the baby’s RBCs. PCR-based assays showed twin 
A (boy) was KEL*841T/C (KEL*03/KEL*04), which is predicted 
to encode Kp(a+b+). Twin B (girl) was KEL*841C/C (KEL*04/
KEL*04), which is predicted to encode Kp(a–b+). We describe 
the first reported case of probable suppression of erythropoiesis 
attributable to anti-Kpa. One twin born to a woman whose serum 
contained anti-Kpa experienced HDFN while the other did not. 
Based on DNA analysis, the predicted blood type of the affected 
twin was Kp(a+b+) and that of the unaffected twin was Kp(a–b+). 
The laboratory findings and clinical course of the affected twin 
were consistent with suppression of erythropoiesis in addition 
to immune RBC destruction. Immunohematology 2011;27: 
58–60.
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The first antigen in the Kell blood group system, K, was 
discovered in 1946 as the result of hemolytic disease of the 
newborn. The system now includes 31 antigens. Antibodies 
to K, k, Kpa, Kpb, Kpc, Jsa, and Jsb are the most clinically 
important.1 Next to anti-A, anti-B, and anti-D, anti-K is 
the most common immune RBC antibody.2 Antibodies to 
antigens in the Kell blood group system are usually IgG, 
and, notoriously, anti-K, anti-k, and anti-Kpa cause severe 
hemolytic transfusion reactions, as well as severe hemolytic 
disease of the fetus and newborn (HDFN).3,4
It is well known that the titer of anti-K does not correlate 
with the severity of HDFN; indeed, severe HDFN caused 
by anti-K has been associated with lower antibody titers, 
bilirubin levels, and reticulocytosis than has hemolytic 
disease of the newborn caused by anti-D.2,3 The anemia 
seen in these infants is caused by a combination of immune 
destruction and suppression of erythropoiesis in the 
fetus.5,6 Vaughan et al. demonstrated experimentally that 
proliferation of K+ erythroid progenitors was inhibited by 
anti-K, and suggested that the K glycoprotein plays a role in 
erythropoiesis.5
Cases of HDFN involving antibodies to other antigens 
in the Kell system of antibodies are rare. We retrospectively 
report a case of HDFN in twins of a mother whose serum 
contained anti-Kpa. The Kp(a+) twin was anemic, and the 
Kp(a–) twin was not.
Case History
A 31-year-old gravida 3, para 2 woman with a history 
of a negative antibody screen delivered ABO-identical, Rh-
compatible fraternal twins at full term (37 weeks’ gestation). 
The mother had two previous pregnancies delivered by 
cesarean section; no problems were noted in the medical 
record. At delivery, the cord hemoglobin (Hb) for twin A 
(male) was 10.2 g/dL and for twin B (female) was 17.0 g/dL. 
Unfortunately, there were no cord bilirubin or reticulocyte 
counts done for either twin.
Because of anemia, shortly after birth twin A received 
a single-aliquot RBC transfusion that was compatible with 
the maternal serum. On day 1, he received an additional 
single-aliquot transfusion with RBCs and was discharged 
on day 5 with a Hb of 15.1 g/dL and an absolute reticulocyte 
count of 0.16 × 109/L (normal range of 0.125–0.325 × 
109/L). Transfusion was again required on day 25 when the 
Hb reached a nadir of 7.5 g/dL with a decreased absolute 
reticulocyte count of 0.007 m/μL. Additional transfusions 
were given on days 30 and 39 to maintain a Hb level above 
9.0 g/dL. After transfusion of two aliquots on day 39, the 
Hb of twin A was 9.6 g/dL and on day 43 and 52 it was 9.3 
g/dL and 9.5 g/dL, respectively. Two weeks later the Hb was 
10.3 g/dL, and 6 months later it was 12.6 g/dL. The infant’s 
bilirubin peaked at 5 mg/dL on day 1 and fell steadily during 




Standard hemagglutination tests were used throughout. 
The cord blood samples were tested by tube method for 
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ABO, Rh, and direct antiglobulin test (DAT). The maternal 
and paternal samples were tested by MTS gel cards (Ortho 
Clinical Diagnostics, Raritan, NJ).
Polymerase Chain Reaction–Restriction Fragment 
Length Polymorphism Analysis for KEL*03/KEL*04
Genomic DNA was isolated from epithelial cells 
captured by the buccal swabs obtained from the twins 
using a DNA kit (QIAamp DNA Blood Mini Kit, QIAGEN, 
Inc., Valencia, CA). Exon 8 of KEL was amplified using 
a forward oligonucleotide primer (Life Technologies, 
Inc., Gaithersburg, MD) designed within exon 8 
(TACCTGACTTACCTGAATCAGCTGGGAACC) and a 
reverse oligonucleotide primer designed at the 3′ end of 
exon 8 and into intron 8 (tcttctggcccccagttccaggcacCATGA). 
Five microliters of DNA per reaction was amplified by 5 
units of Taq DNA polymerase (HotStarTaq, QIAGEN Inc., 
Valencia, CA) in a 50-μL reaction mixture containing 
2.5 mM MgCl2, 1 × PCR buffer, 0.2 mM dNTPs, and 100 
ng of forward and reverse primer. The PCR amplification 
was achieved in 35 cycles with a final extension time of 10 
minutes, using 62°C as the annealing temperature. The 
PCR 202-bp products were digested using the restriction 
enzyme NlaIII. A restriction enzyme site for this restriction 




At the time of delivery, anti-Kpa was identified in the 
maternal serum. No other unexpected antibodies were 
present in the maternal serum. Tests using the serum 
from twin A and an eluate prepared from his RBCs also 
contained anti-Kpa (Table 1). Antibody testing on days 25, 
30, and 39 demonstrated the persistence of anti-Kpa in the 
baby’s serum.
Polymerase Chain Reaction–Restriction Fragment 
Length Polymorphism Analysis for KEL*03/KEL*04
Twin A (boy) was KEL*841T/C (KEL*03/KEL*04), 
which is predicted to encode Kp(a+b+). Twin B (girl) was 
KEL*841C/C (KEL*04/KEL*04), which is predicted to 
encode Kp(a–b+).
Conclusions
We describe the first reported case of possible 
suppression of erythropoiesis attributable to anti-Kpa. One 
twin born to a woman whose serum contained anti-Kpa 
experienced HDFN and anemia, while the other did not. 
Based on DNA analysis, the predicted blood type of the 
affected twin was Kp(a+b+) and that of the unaffected twin 
was Kp(a–b+). The laboratory findings and clinical course 
of the affected twin were consistent with suppression of 
erythropoiesis in addition to immune RBC destruction. The 
steadily declining bilirubin levels concurrent with a declining 
hemoglobin level and decreased absolute reticulocyte 
count provide supportive evidence for this interpretation. 
It is possible that the change in the reticulocyte count was 
induced, or exacerbated, by transfusion. Although this was 
a retrospective study and not all data were available to us, it 
is worth documenting, especially because one twin was an 
antigen-negative twin and served as a control.
Antigens in the Kell blood group system appear on 
erythroid progenitor cells early in erythropoiesis.7,8 Because 
erythroid progenitor cells do not contain hemoglobin, 
immune destruction of these cells by anti-Kpa could 
explain the absence of hyperbilirubinemia in our patient. 
The restriction of Kell messenger RNA and protein to 
erythroid precursors explains why white blood cell and 
platelet counts remained normal in the affected twin.9,10 
The anemia of the affected twin resolved after 3 months, 
and his Hb has remained within the normal range. Twin B 
had no postdelivery complications and provides a biologic 
control for factors other than maternal alloantibody as a 
cause of the anemia. Although anti-K is most commonly 
associated with erythropoietic suppression, twin A shows 
that antibodies to other antigens in the Kell blood group 
system can also have this capability.
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Table 1. Results of hemagglutination tests
Mother Twin A Twin B Father
ABO/Rh A + A + A + A +
DAT Not tested 4+ 0 Not tested
IAT with  
maternal serum
Not tested Not tested Compatible Incompatible











DAT = direct antiglobulin test; IAT = indirect antiglobulin test.
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